Literature DB >> 14684623

Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone.

Masaaki Inaba1, Kiyoshi Nakatsuka, Yasuo Imanishi, Masakazu Watanabe, Yuji Mamiya, Eiji Ishimura, Yoshiki Nishizawa.   

Abstract

BACKGROUND: The Bio-Intact parathyroid hormone (1-84) assay (Bio-PTH), a newly developed two-site immunochemiluminometric assay, measures exclusively PTH (1-84) in contrast to second-generation "intact PTH" (I-PTH) assays. We investigated the technical performance and clinical significance of this new assay.
METHODS: PTH was measured simultaneously by the Bio-PTH assay and Allegro intact PTH IRMA in sera from Japanese patients with calcium disorders.
RESULTS: Measured Bio-PTH in serum was unaffected by six freeze-thaw cycles and was stable at 4 degrees C for 7 days and during storage at -20 or -80 degrees C over 28 days. The calibration curve was linear to 1800 ng/L. The detection limit was 3.9 ng/L. The intra- and interassay imprecision was <2.8% and 3.5%, respectively, for analyte concentrations spanning the range of the calibration curve. Bio-PTH was unaffected by a 1000-fold excess of PTH (7-84), although I-PTH reacted equally with PTH (7-84) and PTH (1-84). Bio-PTH was correlated with I-PTH in healthy individuals (r = 0.953; P <0.0001; n = 26) and in the full population without renal dysfunction (r = 0.994; P <0.0001; n = 62). In 72 volunteers, mean (SD) Bio-PTH was 22.2 (7.1) ng/L, or 62% of the mean I-PTH [36.1 (22.3) ng/L]. This ratio was 51% in hemodialysis patients (n = 177). Mean Bio-PTH was high in patients with primary hyperparathyroidism [121 (85) ng/L; n = 18] and hemodialysis patients [102 (104) ng/L; n = 177], low in idiopathic hypoparathyroidism [5.5 (2.8) ng/L; n = 4], and within 2 SD of the mean for healthy controls in Paget disease of the bone [34 (15) ng/L; n = 9] and bone metastasis [24 (12) ng/L; n = 8].
CONCLUSION: The Bio-PTH assay is sensitive and precise and produces expected results for patients with the studied disorders of calcium metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684623     DOI: 10.1373/clinchem.2003.026831

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  22 in total

1.  A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism.

Authors:  P Boudou; F Ibrahim; C Cormier; E Sarfati; J C Souberbielle
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

2.  Association of increased active PTH(1-84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D.

Authors:  M Kurajoh; M Inaba; S Yamada; Y Imanishi; T Tsuchida; E Ishimura; Y Nishizawa
Journal:  Osteoporos Int       Date:  2008-02-01       Impact factor: 4.507

3.  Increased active PTH(1-84) fraction as a predictor of poor mortality in male hemodialysis patients.

Authors:  M Inaba; S Okuno; Y Imanishi; E Ishimura; T Yamakawa; S Shoji
Journal:  Osteoporos Int       Date:  2013-09-13       Impact factor: 4.507

4.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

Review 5.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

Review 6.  Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism.

Authors:  J C Souberbielle; P Boudou; C Cormier
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

7.  Dysphoria induced in dialysis providers by secondary hyperparathyroidism.

Authors:  Irfana H Soomro; David S Goldfarb
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

8.  Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism.

Authors:  M Kurajoh; M Inaba; S Okuno; H Nagayama; S Yamada; Y Imanishi; E Ishimura; S Shoji; T Yamakawa; Y Nishizawa
Journal:  Osteoporos Int       Date:  2010-05-07       Impact factor: 4.507

9.  Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients.

Authors:  M Inaba; S Okuno; Y Imanishi; S Yamada; A Shioi; T Yamakawa; E Ishimura; Y Nishizawa
Journal:  Osteoporos Int       Date:  2006-08-05       Impact factor: 4.507

10.  Significance of Bio-intact PTH(1-84) assay in hemodialysis patients.

Authors:  Masaaki Inaba; Senji Okuno; Yasuo Imanishi; Misako Ueda; Tomoyuki Yamakawa; Eiji Ishimura; Yoshiki Nishizawa
Journal:  Osteoporos Int       Date:  2004-08-20       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.